Phase 2, Multiple Dose, Open-Label Study to Determine the Long Term Safety of MLN0002 in Patients With Ulcerative Colitis and Crohn's Disease

Trial Profile

Phase 2, Multiple Dose, Open-Label Study to Determine the Long Term Safety of MLN0002 in Patients With Ulcerative Colitis and Crohn's Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs Vedolizumab (Primary)
  • Indications Crohn's disease; Ulcerative colitis
  • Focus Adverse reactions
  • Sponsors Millennium
  • Most Recent Events

    • 07 Feb 2017 Pooled results assessing pregnancy outcomes from six clinical studies and post marketing safety data published in the Alimentary Pharmacology and Therapeutics.
    • 12 May 2016 Results of long-term integrated safety analysis from two phase II and four phase III trials published in a Takeda media release.
    • 18 Feb 2016 Results of two phase II and four phase III studies published in the Gut.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top